Gritstone Oncology Files for $102 Million Offering

April 23, 2019

On 4/22/19, Gritstone Oncology filed for a $102 Million offering of its common stock. Gritstone trades on NASDAQ under the symbol, “GRTS.” The company currently has a market cap of $394 Million.

Gritstone is developing personalized immunotherapy to fight multiple types of cancer. They have developed an AI platform named, “EDGE” to aid their development efforts. The company is currently in the clinical stage and has four development programs. Its lead product, Granite-001, is in Ph I/II trials.

Granite-001 is a personalized neoantigen based immunotherapy. It has received fast track designation from the FDA for the treatment of colorectal cancer.

As of this writing the stock is down 7.63 percent.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.